Bailard Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 49.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,968 shares of the company's stock after purchasing an additional 4,282 shares during the quarter. Bailard Inc.'s holdings in Novo Nordisk A/S were worth $900,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Hudock Inc. raised its stake in Novo Nordisk A/S by 45.6% during the first quarter. Hudock Inc. now owns 7,731 shares of the company's stock valued at $537,000 after purchasing an additional 2,423 shares in the last quarter. Legacy Capital Wealth Partners LLC raised its stake in Novo Nordisk A/S by 23.3% during the first quarter. Legacy Capital Wealth Partners LLC now owns 6,578 shares of the company's stock valued at $457,000 after purchasing an additional 1,241 shares in the last quarter. Welch & Forbes LLC raised its stake in Novo Nordisk A/S by 1.7% during the first quarter. Welch & Forbes LLC now owns 21,546 shares of the company's stock valued at $1,496,000 after purchasing an additional 370 shares in the last quarter. Altman Advisors Inc. raised its stake in Novo Nordisk A/S by 121.1% during the first quarter. Altman Advisors Inc. now owns 35,260 shares of the company's stock valued at $2,343,000 after purchasing an additional 19,309 shares in the last quarter. Finally, Cullen Frost Bankers Inc. lifted its position in Novo Nordisk A/S by 1.2% in the first quarter. Cullen Frost Bankers Inc. now owns 116,829 shares of the company's stock worth $8,113,000 after buying an additional 1,387 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.
Novo Nordisk A/S Stock Performance
NYSE:NVO traded down $0.97 during trading hours on Friday, reaching $64.32. The company had a trading volume of 8,032,293 shares, compared to its average volume of 7,376,215. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The firm has a market cap of $287.19 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.64. The business's 50 day moving average price is $70.34 and its 200-day moving average price is $74.30. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion for the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on NVO shares. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average target price of $112.00.
Get Our Latest Analysis on Novo Nordisk A/S
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Recommended Stories
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
